SIRPA and lymphoma: ALX148 is in phase I studies in patients with solid tumors and lymphomas in combination with a variety of chemotherapy agents.469 OSE-172 is a monoclonal antibody developed by OSE Immunotherapeutics that targets SIRP-α.